Chronic Hepatitis B

TaqMan PCR quantifies viral load during lamivudine therapy for hepatitis B

Published in Hepatitis Weekly, September 22nd, 2003

TaqMan PCR quantifies viral load during lamivudine therapy for hepatitis B.

"Monitoring of hepatitis B virus (HBV) levels in serum plays an important role in the management of chronic hepatitis B in patients receiving lamivudine. We evaluated the usefulness of real-time quantitative polymerase chain reaction (TaqMan PCR) for the measurement of HBV DNA. The subjects were 22 patients with chronic hepatitis B treated with lamivudine for 4-12 months," scientists in Japan reported.

"HBV DNA was measured by TaqMan PCR. For comparison, HBV DNA was also measured in 88 sera by branched DNA (bDNA) assay, transcription-mediated amplification (TMA) assay, and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2003-09-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry